Reviews/Adhd Pharmacotherapy/Stimulants most effective pharmacotherapy for attention-deficit/hyperactivity disorder
Stimulant Efficacy · ADHD-STIM-01 · v2
The papers here show clearly that methylphenidate reduces ADHD symptoms in children, both in controlled trials and in real-world clinical care [1][2][6][9]. They also show it works better than atomoxetine, a non-stimulant, in three separate datasets [3][4][8]. But the claim also names amphetamine-based stimulants, and not one paper in this set actually studies an amphetamine. The claim puts a precise number on the effect (0.8 to 1.0), yet the only paper reporting a standardized effect size gives a much wider range [9], and the word 'most effective' is only ever tested against a single alternative drug. Because the amphetamine half, the exact number, and the 'most effective' ranking are all unsupported by what is here, the panel treated the claim as worded as overreaching what the evidence proves.
This corpus consistently demonstrates that methylphenidate is highly efficacious for paediatric ADHD across a dose-response titration trial [1], an extended-release phase 3 trial [6], a crossover trial [9], a real-world observational cohort [2], and a within-subjects dosing manipulation [7]. It shows methylphenidate outperforms atomoxetine on response rate (84.6% vs 63.3%) [3], on core symptoms in a head-to-head trial [4], and in a psychostimulant-versus-non-psychostimulant comparison [8]. The only standardized effect sizes reported are Cohen's ranging from -0.41 to -1.64 [9]; [6] reports a raw SKAMP least-squares mean difference of -8.6 rather than a standardized effect. No paper in the corpus studies an amphetamine-based stimulant; [8] names amphetamines only in a class definition. The contested point: The evidence does not divide on whether methylphenidate works — that is agreed — but on whether the corpus can carry the claim as written. The pressure points are the untested amphetamine component, the precise 0.8 to 1.0 effect-size band that no paper reports, and the 'most effective' ranking that is checked only against atomoxetine [3][4][8].
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Adhd Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Half the named intervention is untested: no corpus paper studies amphetamine-based stimulants; [8] only names them in a class definition. The amphetamine claim is unsupported extrapolation.
The 0.8-1.0 effect-size figure is not carried by the corpus. Only [9] reports standardized effect sizes (Cohen's -0.41 to -1.64), a range substantially wider than claimed; [6] reports only a raw SKAMP difference.
Where it remains uncertain. No corpus paper studies amphetamines, and the sole standardized effect-size datapoint spans -0.41 to -1.64 [9], not the claimed 0.8 to 1.0.
Aleatory
Response varies across children; [1] reports positive linear dose-response in only 73-88% of individuals, so per-patient benefit is not guaranteed.
Epistemic
The corpus contains zero studies of amphetamine-based stimulants; [8] names them only in a class definition, leaving that half of the claim unknown.
Inferential
Ranking methylphenidate as 'most effective' is inferred from comparison against atomoxetine alone [3][4][8], with no guanfacine, clonidine, bupropion, or amphetamine arm.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes strong MPH efficacy in children in a placebo-controlled RCT.
“Methylphenidate (MPH) is highly efficacious in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) in children.”
Panel auditInternal validity: high · scope of inference: 5-13-year-old children with DSM-5 ADHD; MPH dose-response versus placebo on parent/teacher ratings.Key limitations: small sample · no active comparator · no standardized effect size reported · no amphetamine tested
Supports MPH superiority over a non-stimulant comparator in a large real-world cohort.
“The response rates were 84.6% in the MPH-treated group and 63.3% in the ATX-treated group.”
Panel auditInternal validity: medium · scope of inference: Medication-naive children with ADHD in a real-world setting; MPH versus atomoxetine only.Key limitations: non-randomized · single non-stimulant comparator only · no amphetamine · no effect size for response
Placebo-controlled phase 3 confirmation of MPH efficacy, reported as a raw scale difference not a standardized effect size.
“significant improvements were demonstrated with PRC-063 versus placebo (p < 0.0001) when SKAMP-Combined scores were averaged over the 13-hour full-day laboratory classroom (least squares mean difference = -8.6).”
Panel auditInternal validity: high · scope of inference: Children 6-12 with ADHD; single-day laboratory-classroom SKAMP outcomes for extended-release MPH versus placebo.Key limitations: sample size not reported · no active comparator · surrogate lab-classroom endpoint · no standardized effect size
Uncontrolled observational response rate (81.2% responded) has no comparison arm, so the direction on a comparative/effect-size claim is not determinable from the abstract.
Panel auditInternal validity: low · scope of inference: 207 recently-diagnosed, drug-naive children given titrated MPH over 12 weeks in routine clinical care.Key limitations: uncontrolled · no comparator · response rate not attributable to drug · no effect size
4 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The core MPH efficacy is well evidenced but the claim's amphetamine component, precise effect-size band, and cross-class superlative are all unsupported as worded, so the compound claim is Doubtful.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No amphetamine-based stimulant data. Half the named intervention has no corpus evidence, so the claim's amphetamine component is unsupported. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A head-to-head RCT of an amphetamine-based stimulant versus methylphenidate and placebo in paediatric ADHD with standardized effect-size reporting.
Open question: Do amphetamine-based stimulants match methylphenidate for efficacy in childhood and adolescent ADHD? Why it is still open: No corpus paper studies an amphetamine; [8] names them only in a class definition.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19